# Innate Pharma (IPHA) — Earnings

IPHA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ipha/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q4 2025 |
| Period end | Dec 31, 2025 |
| EPS actual | −$0.35 |
| EPS estimate | −$0.35 |
| EPS surprise | +0.00% |
| Revenue surprise | +0.00% |
| Revenue | $5.7M |
| Revenue estimate | $5.7M |
| Reported | Mar 26, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1598599/000162828026021168/a2603266kincorporatediph.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/9031151d-d356-25a4-8b6e-a0ab841d1561.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q4 2025 | Mar 26, 2026 | −$0.35 | −$0.35 | 0.00% | $5.7M | $5.7M |

## Frequently Asked Questions

### When did Innate Pharma (IPHA) last report earnings?

Innate Pharma last reported on Mar 26, 2026, covering fiscal Q4 2025.

### Did IPHA beat earnings estimates?

Innate Pharma reported EPS of −$0.35 for Q4 2025, in line with the −$0.35 consensus estimate.

### How much revenue did IPHA report last quarter?

Innate Pharma reported $5.7M in revenue for Q4 2025, against a consensus estimate of $5.7M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).